Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular IG-LIKE DOMAINS which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
| Descriptor ID |
D040262
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950 D12.776.543.750.630.750 D12.776.543.750.750.400.910
|
| Concept/Terms |
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Endothelial Cell Growth Factor
- Receptor, Vascular Permeability Factor
- VEGF Receptors
- Receptors, VEGF
- Vascular Endothelial Cell Growth Factor Receptor
- VPF Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- Vascular Permeability Factor Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in this website by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 8 | 8 |
| 2003 | 1 | 0 | 1 |
| 2004 | 5 | 5 | 10 |
| 2005 | 4 | 5 | 9 |
| 2006 | 2 | 4 | 6 |
| 2007 | 3 | 9 | 12 |
| 2008 | 6 | 7 | 13 |
| 2009 | 4 | 7 | 11 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 8 | 10 |
| 2012 | 2 | 3 | 5 |
| 2013 | 5 | 4 | 9 |
| 2014 | 3 | 5 | 8 |
| 2015 | 7 | 4 | 11 |
| 2016 | 5 | 3 | 8 |
| 2017 | 7 | 8 | 15 |
| 2018 | 2 | 4 | 6 |
| 2019 | 5 | 5 | 10 |
| 2020 | 6 | 1 | 7 |
| 2021 | 1 | 11 | 12 |
| 2022 | 1 | 9 | 10 |
| 2023 | 1 | 9 | 10 |
| 2024 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2024 Jul 01; 150(7):587-597.
-
A method for rapid and reliable quantification of VEGF-cell binding activity. Biochem Biophys Res Commun. 2024 10 01; 727:150321.
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.
-
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
-
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023 09 01; 141(9):834-842.